Advertisement

Surveillance

  • Heikki J. JärvinenEmail author
  • Jukka-Pekka Mecklin
Chapter
Part of the M.D. Anderson Solid Tumor Oncology Series book series (MDA, volume 5)

Abstract

In Lynch syndrome surveillance aims at prevention of early detection of cancer types observed to occur in significant excess. At present, regular prophylactic examinations have been shown beneficial for colorectal and endometrial cancer, i.e. repeated colonoscopy and endometrial biopsy combined with ultrasonograpy. For other less common cancer types involved, no proven benefit has been shown. The guidelines of identifying Lynch syndrome, the principles of genetic testing, and arranging surveillance are reviewed in this article, also shortly dealing with prophylactic surgery and possible chemoprevention in future.

Keywords

Colonoscopy Colorectal carcinoma Endometrial carcinoma Lynch syndrome Cancer prevention Polypectomy Endometrial biopsy Prophylactic surgery 

References

  1. 1.
    Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110:1020–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6:105–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Wilson JMG, Junger G. Principles and practice of screening for disease. Public Health Papers 34. WHO, Geneva; 1968Google Scholar
  5. 5.
    Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193–200.PubMedGoogle Scholar
  6. 6.
    Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293:1986–94.PubMedCrossRefGoogle Scholar
  7. 7.
    Vasen HF, Watson P, Mecklin J-P, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology. 1999;116:1453–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354:271–2763.CrossRefGoogle Scholar
  10. 10.
    Engel C, Forberg C, Holinski-Feder E, et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer. 2006;118:115–22.PubMedCrossRefGoogle Scholar
  11. 11.
    Lerman G, Hughes C, Trock B, et al. Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA. 1999;281:1618–22.PubMedCrossRefGoogle Scholar
  12. 12.
    Aktán-Collán K, Mecklin J-P, Järvinen HJ, et al. Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer. 2000;89:44–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Pylvänäinen K, Kairaluoma M, Mecklin J-P. Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Fam Cancer. 2006;5:175–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Jass JR, Stewart SM, Lane MR. Hereditary non-polyposis colorectal cancer – morphologies, genes and mutations. Mutat Res. 1994;310:125–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet. 2005;42:491–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Mecklin J-P, Järvinen HJ, Peltokallio P. Cancer family syndrome. Genetic analysis of 22 Finnish kindreds. Gastroenterology. 1986;90:328–33.PubMedGoogle Scholar
  17. 17.
    Aarnio M, Mecklin J-P, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64:430–3.PubMedCrossRefGoogle Scholar
  18. 18.
    de Jong AE, Nagengast FM, Kleibeuker JH, et al. What is the appropriate screening protocol in Lynch syndrome? Fam Cancer. 2006;5:373–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Renkonen-Sinisalo L, Aarnio M, Mecklin J-P, et al. Surveillance improves survival on colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev. 2000;24:137–42.PubMedGoogle Scholar
  20. 20.
    de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum. 2002;45:1588–94.CrossRefGoogle Scholar
  21. 21.
    Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Renkonen-Sinisalo L, Kivisaari A, Kivisaari L, et al. Utility of computed tomographic colonography in surveillance for hereditary nonpolyposis colorectal cancer syndrome. Fam Cancer. 2007;6:135–40.PubMedCrossRefGoogle Scholar
  23. 23.
    Wijnen J, de Leeuw W, Vasen H, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet. 1999;23:142–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Dove-Edvin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer. 2002;94:1708–12.CrossRefGoogle Scholar
  25. 25.
    Rijcken FE, Mourits MJ, Kleibeuker JH, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2003;91:74–80.PubMedCrossRefGoogle Scholar
  26. 26.
    Renkonen-Sinisalo L, Bützow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer. 2007;120:821–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Renkonen-Sinisalo L, Sipponen P, Aarnio M, et al. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol. 2002;37:574–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Myrhoj T, Andersen M-B, Bernstein I. Screening for urinary tract cancer with urine cytology in HNPCC-families. Fam Cancer. 2007;6:346 (abstr).Google Scholar
  29. 29.
    Church JM. Prophylactic colectomy in patients with hereditary non-polyposis colorectal cancer. Ann Med. 1996;28:479–82.PubMedCrossRefGoogle Scholar
  30. 30.
    Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Sandler RS, Halabi S, Baron JB. A randomized trial of aspirin to prevent colorectal adenomas with previous colorectal cancer. N Engl J Med. 2003;348:883–90.PubMedCrossRefGoogle Scholar
  32. 32.
    Steinbach GD, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–52.PubMedCrossRefGoogle Scholar
  33. 33.
    Lu K, Loose D, Lynch H, et al. Preliminary analysis of a prospective, multi-center endometrial cancer chemoprevention study in women with Lynch syndrome. Fam Cancer. 2007;6:347 (abstr).Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of SurgeryHelsinki University Central HospitalHelsinkiFinland

Personalised recommendations